IMS Health Holdings Inc. (IMS) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of IMS Health Holdings Inc. (NYSE:IMS) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. The brokerage currently has $34.00 target price on the stock.
According to Zacks, “IMS Health Holdings, Inc. engages in providing information, services, and technology to the healthcare industry worldwide. The company develops healthcare measurement solutions, such as IMS LifeLink program, IMS NPA Market Dynamics, IMS Xponent Prescribing Dynamics, IMS PlanTrak Market Dynamics, and Specialty Market Dynamics. It serves pharmaceutical, payers, government, providers, pharmacies, consumer health, pharmaceutical distribution, and financial community sectors. The company also provides consumer health insights, forecasting solutions, payer insights, pharmaceutical measurement solutions, and publications. IMS Health Holdings, Inc. is based in Danbury, Connecticut. “
Separately, TheStreet lowered IMS Health Holdings from a buy rating to a hold rating in a research note on Monday, August 29th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. IMS Health Holdings currently has a consensus rating of Buy and a consensus target price of $31.00.
Shares of IMS Health Holdings (NYSE:IMS) opened at 31.34 on Wednesday. IMS Health Holdings has a 1-year low of $22.36 and a 1-year high of $31.59. The stock has a 50 day moving average price of $29.83 and a 200-day moving average price of $27.37. The stock has a market capitalization of $10.32 billion, a PE ratio of 76.07 and a beta of 0.83.
IMS Health Holdings (NYSE:IMS) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.03. The business earned $802 million during the quarter, compared to analyst estimates of $796.93 million. IMS Health Holdings had a return on equity of 30.61% and a net margin of 4.45%. The company’s revenue for the quarter was up 112.4% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. On average, analysts forecast that IMS Health Holdings will post $1.64 earnings per share for the current year.
Several large investors have recently modified their holdings of IMS. Acrospire Investment Management LLC raised its stake in shares of IMS Health Holdings by 31.3% in the second quarter. Acrospire Investment Management LLC now owns 4,200 shares of the company’s stock worth $107,000 after buying an additional 1,000 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of IMS Health Holdings by 9.3% in the second quarter. Nordea Investment Management AB now owns 4,811 shares of the company’s stock worth $122,000 after buying an additional 411 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of IMS Health Holdings by 14.0% in the second quarter. LS Investment Advisors LLC now owns 4,982 shares of the company’s stock worth $126,000 after buying an additional 611 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of IMS Health Holdings by 83.8% in the second quarter. BNP Paribas Arbitrage SA now owns 4,993 shares of the company’s stock worth $127,000 after buying an additional 2,276 shares in the last quarter. Finally, Seven Eight Capital LLC acquired a new stake in shares of IMS Health Holdings during the first quarter worth about $191,000. 90.25% of the stock is owned by hedge funds and other institutional investors.
About IMS Health Holdings
IMS Health Holdings, Inc (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Company’s data set contains over 10 petabytes of data and over 500 million patient records. It serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMS Health Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMS Health Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.